CorMedix files Melinta acquisition financials; Melinta 2024 revenue $120M, net loss $4.7M

CorMedix Inc.

Melinta 2024 total revenue $119.97M (product $106.3M) vs $105.6M in 2023; net loss narrowed to $4.7M from $36.0M.
Cash and equivalents $49.8M at Dec 31, 2024; total assets $177.6M, notes payable $84.9M.
CorMedix acquired Melinta on Aug 29, 2025 for undisclosed terms; Melinta markets seven anti-infective brands including BAXDELA, VABOMERE, ORBACTIV.

item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.